title: Novel Levodopa Formulations for Parkinson's Disease.
abstract: Levodopa remains the most effective treatment for Parkinson's disease and is considered the gold standard therapy. However, disease progression and changes in the gastrointestinal tract result in a declining window of treatment response in a majority of patients. Efforts have been made recently to improve levodopa bioavailability either by developing more effective oral formulations or by innovating routes of administration (intestinal infusion, transcutaneous or inhaled levodopa). IPX066 is a novel levodopa-carbidopa (LD/CD) oral formulation combining immediate-release (IR) and extended-release (ER) LD/CD recently approved in the USA and the EU. Levodopa-carbidopa intestinal gel (LCIG) is an approved therapy consisting of a suspension of levodopa and carbidopa infused directly into the proximal jejunum via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube through a portable infusion pump. Ongoing studies are evaluating the 'accordion pill' (AP09004), an ER LD/CD formulation with gastroretentive properties. ND0612 is a proprietary liquid formulation of LD/CD that enables subcutaneous administration via a small patch-pump device, and CVT-301 is a levodopa inhalation powder with rapid onset of action; both are currently in active studies. Other novel formulations have been discontinued, including DM-1992, which is a bilayer formulation containing an IR LD/CD layer and an ER LD/CD layer with gastroretentive properties, and XP21279, a novel oral levodopa prodrug that is absorbed from the small and large intestine by high-capacity nutrient transporters expressed throughout the gastrointestinal system. ODM-101 is a new oral formulation of levodopa/carbidopa/entacapone that contains a higher amount of carbidopa (65 or 105 mg), but no active studies are underway. The current review aims to summarize the pharmacokinetic aspects, clinical efficacy, and potential adverse events of novel levodopa formulations currently available or under development.
authors.affiliation: Movement Disorders Centre and Edmond J. Safra Program in Parkinson's Disease, Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, 399 Bathurst Street MCL7-412, Toronto, ON, M5T 2S8, Canada.
authors.forename: Maria Eliza
authors.initials: ME
authors.lastname: Freitas
authors.affiliation: Movement Disorders Centre and Edmond J. Safra Program in Parkinson's Disease, Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, 399 Bathurst Street MCL7-412, Toronto, ON, M5T 2S8, Canada.
authors.forename: Marta
authors.initials: M
authors.lastname: Ruiz-Lopez
authors.affiliation: Movement Disorders Centre and Edmond J. Safra Program in Parkinson's Disease, Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, 399 Bathurst Street MCL7-412, Toronto, ON, M5T 2S8, Canada. sfox@uhnresearch.ca.
authors.forename: Susan H
authors.initials: SH
authors.lastname: Fox
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use; D002396:Catechols / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004338:Drug Combinations; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009570:Nitriles / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D002396:Catechols; D004338:Drug Combinations; D009570:Nitriles; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; C071192:entacapone; D002230:Carbidopa